September 24, 2016 11:45 PM ET

Life Sciences Tools and Services

Company Overview of Celerion Inc.

Company Overview

Celerion Inc. provides early clinical research services for pharmaceutical and biotechnology companies in the United States and internationally. The company focuses on delivering applied translational medicine to support early drug development decisions. Its services include global clinical research (Phase I and II, and NDA-enabling clinical pharmacology study conduct); clinical pharmacology sciences (modeling and simulation, study design and protocol development, clinical data sciences, biostatistics, pharmacokinetics/pharmacodynamics (PK/PD), and medical writing and reporting); global bioanalytical services (discovery to late stage services with capabilities in small and large drug, and me...

621 Rose Street

Lincoln, NE 68502-2040

United States

Founded in 2010





Key Executives for Celerion Inc.

Chief Executive officer and President
Age: 63
Chief Financial Officer
Chief Cardiologist and Global Medical Director of Cardiac Safety Services
Senior Vice President of Global Clinical Development
Vice President of Global Business Development
Compensation as of Fiscal Year 2016.

Celerion Inc. Key Developments

Celerion Inc. Presents at BIO-Europe 2015, Nov-02-2015

Celerion Inc. Presents at BIO-Europe 2015, Nov-02-2015 . Venue: Munich, Germany.

Celerion Expands Ophthalmological Capabilities to Patient Populations in Collaboration with Queen's University, Belfast

Celerion, announced the expansion of ophthalmological services in the Belfast, Northern Ireland UK facility, by building on the successful relationship with Queen's University in Belfast. Celerion will expand its collaboration with Queen's University for access to patient populations, specialized procedures and their scientific expertise in this area. This new focus will enable Celerion to apply expertise acquired from several years of performing precise ophthalmologic measurements as part of assessing the safety of new drug candidates. By moving beyond clinical safety assessment, Celerion scientists and colleagues at The Centre for Experimental Medicine at Queen's University can perform assessments of drug effect in a controlled research environment. The focus will be on patients with eye diseases such as diabetic retinopathy, age-related macular degeneration, glaucoma, and retinal vein occlusions.

Similar Private Companies By Industry

Company Name Region
10X Genomics, Inc. United States
4G Clinical, Inc. United States
AAPharmaSyn LLC United States
Abiant, Inc. United States
aBioBot, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Celerion Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at